Karla J. Cowley

Peter MacCallum Cancer Centre

Papers

2

Total Citations

14

H-Index

1

About

Dr. Karla J. Cowley is a translational cancer biologist and virologist whose work bridges rare gynecologic malignancies and antiviral host-pathogen interactions. Her primary research focuses on low-grade serous ovarian carcinoma (LGSOC), a rare epithelial ovarian cancer with distinct molecular features from high-grade serous carcinoma. Dr. Cowley’s landmark 2024 study, which has garnered 13 citations, employed high-throughput drug screening to identify novel therapeutics for LGSOC—a disease historically underrepresented in pivotal clinical trials. This work addresses a critical gap in ovarian cancer management by providing evidence-based treatment avenues for a patient population often excluded from standard-of-care studies. More recently, Dr. Cowley has expanded into virology, conducting genome-wide analyses of host-encoded microRNAs that modulate SARS-CoV-2 infection. Her 2025 study leverages CRISPR screening to map cellular pathways exploited by the virus, offering potential targets for antiviral therapeutics. By combining functional genomics with translational drug discovery, Dr. Cowley’s research exemplifies how molecular insights can directly inform clinical strategies—whether in rare cancers or emerging infectious diseases. Her work is particularly valuable for students and researchers interested in the intersection of oncology, virology, and precision medicine.

Research Focus

Key Achievements

1
H-Index
2
Papers
14
Total Citations
7
Avg Citations/Paper
🏆 Most Cited Paper
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma
13 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 15
🏛 Institutions: Peter MacCallum Cancer Centre

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago